A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in
chemo-naive elderly patients with advanced non-small cell lung cancer. Patients will be
randomized to receive either Tarceva (150 mg po daily) or vinorelbine (60 mg/m2 on days 1 and
8 of cycle 1 and 80 mg/m2 for the other 21 days cycles). The anticipated time on study
treatment is until disease progression.